Study summary
A once-daily pill cut attacks by 83%
83%fewer monthly attacks than with placebo
What was tested
Deucrictibant extended-release, an oral bradykinin B2 receptor blocker taken daily, against placebo, to prevent attacks.
What they found
- Mean monthly attack rate fell 83% compared with placebo.
- Met its primary and all secondary goals.
What it means
Could become an oral alternative to injected prevention; a soft-capsule form is tested for attacks.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.